Hemopatch® is effective and safe to use: real-world data from a prospective European registry study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109735" target="_blank" >RIV/00843989:_____/22:E0109735 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/content/pdf/10.1007/s13304-022-01353-y.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s13304-022-01353-y.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13304-022-01353-y" target="_blank" >10.1007/s13304-022-01353-y</a>

Result language

angličtina

Original language name

Hemopatch® is effective and safe to use: real-world data from a prospective European registry study

Original language description

Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30212 - Surgery

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Updates in surgery

ISSN

2038-131X

e-ISSN

2038-3312

Volume of the periodical

74

Issue of the periodical within the volume

5

Country of publishing house

IT - ITALY

Number of pages

11

Pages from-to

1521-1531

UT code for WoS article

000842773300001

EID of the result in the Scopus database

2-s2.0-85136546305